| | 113-52-0 Basic information More.. |
| Product Name: | Imipramine hydrochloride | | Synonyms: | Imipramine hydrochloride,10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride, 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine hydrochloride;Imipramine Hydrochloride (200 mg);Methanol(test Imipramine HCl, 1.0 mg/mL as free base);10,11-Dihydro-N,N-dimithyl-5,H-dibenz[b,f]azepine-5-propanamine;5-(3-dimethylaminopropyl)-10,11-dihydro-5h-dibenz(b,f)azepinehydrochloride;tofranil;tofranile;LABOTEST-BB LT00452014 | | CAS: | 113-52-0 | | MF: | C19H25ClN2 | | MW: | 316.87 | | EINECS: | 204-030-7 | | Mol File: | 113-52-0.mol |  |
Use
Imipramine hydrochloride, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride(Tofranil), is the lead compound of the TCAs. It is also a closerelative of the antipsychotic phenothiazines (replace the10–11 bridge with sulfur, and the compound is the antipsychoticagent promazine). It has weaker D2 postsynaptic blockingactivity than promazine and mainly affects amines (5-HT,NE, and DA) via the transporters. As is typical of dimethylaminocompounds, anticholinergic and sedative (central H1block) effects tend to be marked. The compound per se has a tendency toward a high 5-HT-to-NE uptake block ratio andprobably can be called a serotonin transport inhibitor(SERTI). Metabolic inactivation proceeds mainly by oxidativehydroxylation in the 2-position, followed by conjugationwith glucuronic acid of the conjugate. Urinary excretion predominates(about 75%), but some biliary excretion (up to25%) can occur, probably because of the large nonpolargrouping. Oxidative hydroxylation is not as rapid or completeas that of the more nucleophilic ring phenothiazine antipsychotics;consequently, appreciable N-demethylation occurs,with a buildup of norimipramine (or desimipramine).
|
|
113-52-0
Recommend Suppliers |
|